Prevalence of benign tumors among patients with multiple sclerosis

Aryan Rafiee Zadeh, Mehrdad Farrokhi, Masoud Etemadifar, Ali Amani Beni


Multiple sclerosis (MS), an inflammatory autoimmune disease, affects almost 1% of world’s population in which myelin sheaths of neurons are targeted by immune cells. Association of different factors and diseases with MS provides new insights into possible pathogenesis and treatment for this disease. In this regard, we investigated the association of benign tumors with MS disease by studying total Isfehan multiple sclerosis (TIMS) records for MS patients registered in Isfahan Multiple Sclerosis Society (IMSS) who had developed any kind of benign tumors whether before MS diagnosis or after it. This study was performed in Isfahan province, third large province of Iran, with 4,815,863 populations located 1590 meters above sea level between latitudes 30 and 34 degrees north of the equator, and longitude 49-55 east. Among 4950 registered patients, 28 patients were discovered to have three types of benign tumors; pituitary adenoma in 22, meningioma in 5 and lipoma in 1 patient. The incidence rate of developing pituitary adenoma and meningioma were higher than in general population (OR 95%CI: 1.110; range: 0.731-1.685 and 1.035; range: 0.431-2.487 respectively) but these findings were not statistically significant (p= 0.624 for pituitary adenoma and p= 0.939 for meningioma). But the incidence rate for lipoma was lower among MS patients (OR 95%CI: 0.020; range: 0.003-0.143) which was statistically significant (p <0.001).


Multiple sclerosis, benign tumors, pituitary adenoma, meningioma, lipoma

Full Text:



Hoglund RA, Maghazachi AA. Multiple sclerosis and the role of immune cells. World J Exp Med 4:27-37,

Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 51:137-157, 1975.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846, 2005.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452, 1983.

Anderson M, Hughes B, Jefferson M, Smith WT, Waterhouse JA. Gliomatous transformation and demyelinating diseases. Brain 103:603-622,1980.

Vieregge P, Nahser HC, Gerhard L, Reinhardt V, Nau HE. Multiple sclerosis and cerebral tumor. Clin Neuropathol 3:10-21, 1984.

Zimmerman HM, Netsky MG. The pathology of multiple sclerosis. Res Publ Assoc Res Nerv Ment Dis 28:271-312, 1950.

Khan OA, Bauserman SC, Rothman MI, Aldrich EF, Panitch HS. Concurrence of multiple sclerosis and brain tumor: clinical considerations. Neurology 48:1330-1333, 1997.

Currie S, Urich H. Concurrence of multiple sclerosis and glioma. Journal of neurology, neurosurgery, and psychiatry 37:598-605, 1974.

Aarli JA, Mork SJ, Myrseth E, Larsen JL. Glioblastoma associated with multiple sclerosis: coincidence or induction? Eur Neurol 29:312-316, 1989.

Markou A, Tsigou K, Papadogias D, Kossyvakis K, Vamvakidis K, Kounadi T, et al. A unique case of a benign adrenocortical tumor with triple secretion of cortisol, androgens, and aldosterone: development of multiple sclerosis after surgical removal of the tumor. Hormones 4:226-30, 2005.

Love S. Demyelinating diseases. J Clin Pathol 59:1151-1159, 2006.

Pender MP. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair? J Clin Neurosci 11:689-692, 2004.

Naderi A. Prolactin-induced protein in breast cancer. Adv Exp Med Biol 846:189-200, 2015.

Suarez AL, Lopez-Rincon G, Martinez Neri PA, Estrada-Chavez C. Prolactin in inflammatory response. Adv Exp Med Biol 846:243-264, 2015.

Correale J, Farez MF, Ysrraelit MC. Role of prolactin in B cell regulation in multiple sclerosis. J Neuroimmunol 269:76-86, 2014.

Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 11:A465-470, 2012.

Peeva E, Venkatesh J, Michael D, Diamond B. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother 58:310-319, 2004.

Etemadifar M, Najafi MA, Najafi MR, Alavi A, Nasr Z, Farokhi M, et al. Multiple sclerosis and hyperprolactinemia: a case-control study. Acta Neurol Belg 115:253-257, 2014.

Azar ST, Yamout B. Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res 25:207-214, 1999.

Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler 19:15-23, 2013.

Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Sfagos C. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis. J Neuroendocrinol 22:503-508, 2010.

Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthr Rheumat 60:1743-1752, 2009.

de Mello-Coelho V, Villa-Verde DM, Dardenne M, Savino W. Pituitary hormones modulate cell-cell interactions between thymocytes and thymic epithelial cells. J Neuroimmunol 76(1-2):39-49, 1997.

Matera L, Contarini M, Bellone G, Forno B, Biglino A. Up-modulation of interferon-gamma mediates the enhancement of spontanous cytotoxicity in prolactin-activated natural killer cells. Immunol 98:386-392, 1999.

Matera L, Mori M, Galetto A. Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus 10:728-734, 2001.

Mitosek-Szewczyk K, Stelmasiak Z. Problems in diagnosing cranial base meningioma in patients with multiple sclerosis. Neurolog Sci 24:296-298, 2003.

Ludwig N, Keller A, Heisel S, Leidinger P, Rheinheimer S, Andres C, et al. Novel immunogenic antigens increase classification accuracy in meningioma to 93.84%. Int J Cancer 128:1493-1501, 2011.

Batay F, Al-Mefty O. Growth dynamics of meningiomas in patients with multiple sclerosis treated with interferon: report of two cases. Acta Neurochirurg 144:365-368, 2002.

Drevelegas A, Xinou E, Karacostas D, Parissis D, Karkavelas G, Milonas I. Meningioma growth and interferon beta-1b treated multiple sclerosis: coincidence or relationship? Neuroradiology 47:516-19, 2005.

Vieira RG, Vale TC, Rocha CF, Araujo CR, Lana-Peixoto MA, Brazilian Committee for T, et al. Meningioma after immunomodulation for multiple sclerosis. Arq Neuropsiquiatr 70:75-76, 2012.

Costa MF, Novis SA, Niemeyer Filho P, Pimentel ML, Novis RF, Duarte F. Multiple sclerosis, spinal cord ependymoma and intracranial meningioma: case report. Arq Neuropsiquiatr 58:1133-1137, 2000.

Schneider B, Pulhorn H, Rohrig B, Rainov NG. Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prev 29:440-447, 2005.

Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study C. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Brit J Cancer 99:185-190, 2008.

Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer 110:471-476, 2007.

Wigertz A, Lonn S, Hall P, Auvinen A, Christen-

sen HC, Johansen C, et al. Reproductive factors and risk of meningioma and glioma. Cancer Epidem Biomarkers Prev 17:2663-2670, 2008.

Sena A, Couderc R, Vasconcelos JC, Ferret-Sena V, Pedrosa R. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 317:47-51, 2012.

Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 47:161-168, 1993.

Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril 94:2835-2837, 2010.

Berman D, Miller NR. New concepts in the management of optic nerve sheath meningiomas. Ann Acad Med Singapore 35:168-174, 2006.

Bosch MM, Wichmann WW, Boltshauser E, Landau K. Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol 124:379-385, 2006.

Fernandez MJ, Davis RP, Nora PF. Gastrointestinal lipomas. Arch Surg 118:1081-1083, 1983.

Jeong HK, Cho SB, Seo TJ, Lee KR, Lee WS, Kim HS, et al. Autoamputation of a giant colonic lipoma. Gut Liver 5:380-382, 2011.